Polymer Factory already sells SpheriCal® to commercial customers, confirming that the platform is fully commercialized. Sales increased by approximately 150% during 2025 compared to the previous year. The instrument analysis industry continues to demonstrate attractive growth rates and strong profitability, while end customers within biotechnology and life science are driving increased demand for improved analytical performance-where calibration standards play a critical role.

SpheriCal® benefits from very high gross margins, strong intellectual property protection, and scalable manufacturing. Polymer Factory holds two patent families related to SpheriCal®, approved in five and three countries respectively, and the company's production processes and formulations are difficult to replicate. Importantly, the platform can be scaled efficiently without the need for significant capital investments.

During 2026, Polymer Factory expects to further expand the SpheriCal® platform through continued commercialization of calibration standards for several key application areas, including IM-MS, DMA-MS, ESI, LC-MS, and DESI-MS. In addition, the company is actively developing solutions for MALDI-MSI, a rapidly growing application area.

The market potential for calibration standards is substantial. Should Polymer Factory capture 20% of the global calibrant market, the estimated sales potential would amount to several billion SEK.

Key players in the field include Bruker, Agilent, Waters, Thermo Fisher, and Shimadzu, alongside leading universities and clinical institutions. Polymer Factory has established, to varying degrees, meaningful and growing collaborations with several of these stakeholders.

"We have all the key components in place and a solid structure that enables multiple commercial partnerships or potential M&A opportunities," says Mats Wallnér, CEO of Polymer Factory.